CKD-701
Phase 3Small molecule
Chong Kun Dang PharmaceuticalCKD-701 is one of 44 small molecule programs targeting Macular Degeneration. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Macular Degeneration
#DrugCompanyPhaseTrials
1Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Visudyne
BBausch Health Americas, Inc.
Approved
Bayer Aspirin
BayerPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Stivarga
BayerPhase 2
Soliris
AstraZenecaPhase 2
Avastin
BBio-Thera Solutions
Phase 2
Intravitreal Bevacizumab
AAsociación para Evitar la Ceguera en México
Phase 3
Votrient
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CKD-701. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details